CMV-specific immunotherapy

被引：25

作者：

Einsele, H ^{[1
]}

Hebart, H ^{[1
]}

机构：

[1] Univ Tubingen, Med Klin & Poliklin, Abt 2, D-7400 Tubingen, Germany

来源：

HUMAN IMMUNOLOGY | 2004年 / 65卷 / 05期

关键词：

CMV; T cells; adoptive immunotherapy;

D O I：

10.1016/j.humimm.2004.02.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Considerable progress has been made in our understanding of the immunobiology of infections in immunocompromised hosts. Insights derived from animal model and human studies have provided the rationale to investigate immunotherapy with alphabeta+ T cells to restore responses considered essential for protective immunity to cytomegalovirus infection. Future studies will address the role of adoptive immunotherapy using different immunoeffector cell populations to improve control of virus infection. The use of genetically modified T cells has already been evaluated clinically and offers the potential for improving safety and efficacy and removing obstacles to successful immunotherapy. Although these studies are in the early stages and present considerable technical challenges, the results suggest that cellular immunotherapy will be a fruitful area for investigation in future years. Human Immunology 65, 558-564 (2004). (C) American Society for Histocompatibility and Immunogenetics, 2004. Published by Elsevier Inc.

引用

页码：558 / 564

页数：7

共 42 条

[31]

REUSSER P, 1991, BLOOD, V78, P1373

[32] PHASE-I STUDY OF CELLULAR ADOPTIVE IMMUNOTHERAPY USING GENETICALLY MODIFIED CD8+ HIV-SPECIFIC T-CELLS FOR HIV SEROPOSITIVE PATIENTS UNDERGOING ALLOGENEIC BONE-MARROW TRANSPLANT [J].

RIDDELL, SR ;

GREENBERG, PD ;

OVERELL, RW ;

LOUGHRAN, TP ;

GILBERT, MJ ;

LUPTON, SD ;

AGOSTI, J ;

SCHEELER, S ;

COOMBS, RW ;

COREY, L .

HUMAN GENE THERAPY, 1992, 3 (03) :319-338

[33]

RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545

[34]

RIDDELL SR, 1992, SCIENCE, V257, P238

[35] T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients [J].

Riddell, SR ;

Elliott, M ;

Lewinsohn, DA ;

Gilbert, MJ ;

Wilson, L ;

Manley, SA ;

Lupton, SD ;

Overell, RW ;

Reynolds, TC ;

Corey, L ;

Greenberg, PD .

NATURE MEDICINE, 1996, 2 (02) :216-223

[36] Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy [J].

Rossig, C ;

Bollard, CM ;

Nuchtern, JG ;

Rooney, CM ;

Brenner, MK .

BLOOD, 2002, 99 (06) :2009-2016

[37] Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms [J].

Sauce, D ;

Bodinier, M ;

Garin, M ;

Petracca, B ;

Tonnelier, N ;

Duperrier, A ;

Melo, JV ;

Apperley, JF ;

Ferrand, C ;

Hervé, P ;

Lang, F ;

Tiberghien, P ;

Robinet, E .

BLOOD, 2002, 99 (04) :1165-1173

[38] Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals [J].

Savoldo, B ;

Cubbage, ML ;

Durett, AG ;

Goss, J ;

Huls, MH ;

Liu, ZS ;

Teresita, L ;

Gee, AP ;

Ling, PD ;

Brenner, MK ;

Heslop, HE ;

Rooney, CM .

JOURNAL OF IMMUNOLOGY, 2002, 168 (02) :909-918

[39] Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus [J].

Sester, M ;

Sester, U ;

Gärtner, B ;

Kubuschok, B ;

Girndt, M ;

Meyerhans, A ;

Köhler, H .

JOURNAL OF VIROLOGY, 2002, 76 (08) :3748-3755

[40] Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers [J].

Szmania, S ;

Galloway, A ;

Bruorton, M ;

Musk, P ;

Aubert, G ;

Arthur, A ;

Pyle, H ;

Hensel, N ;

Ta, N ;

Lamb, L ;

Dodi, T ;

Madrigal, A ;

Barrett, J ;

Henslee-Downey, J ;

van Rhee, F .

BLOOD, 2001, 98 (03) :505-512

← 1 2 3 4 5 →